Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
Europe
0
Australia
0
South Africa
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Codinovo
2. Dicodid
3. Dihydrocodeinone
4. Hycodan
5. Hycon
6. Hydrocodeinonebitartrate
7. Hydrocodon
8. Hydrocodone
9. Hydrocodone Tartrate (1:1), Hydrate (2:5)
10. Hydrocon
11. Robidone
1. (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2,3-dihydroxybutanedioic Acid
2. .codon
3. Schembl154972
4. Chembl2062267
1. Hydrocone
2. Multacodin
3. Hydrocodone
Molecular Weight | 449.4 g/mol |
---|---|
Molecular Formula | C22H27NO9 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 4 |
Exact Mass | 449.16858144 g/mol |
Monoisotopic Mass | 449.16858144 g/mol |
Topological Polar Surface Area | 154 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 642 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Analgesics, Opioid
Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)
Antitussive Agents
Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)
Narcotics
Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-23
Pay. Date : 2013-04-09
DMF Number : 19848
Submission : 2006-10-03
Status : Active
Type : II
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Complete
Rev. Date : 2014-03-31
Pay. Date : 2014-03-20
DMF Number : 23681
Submission : 2010-03-31
Status : Active
Type : II
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Complete
Rev. Date : 2013-02-08
Pay. Date : 2012-11-23
DMF Number : 21158
Submission : 2007-12-18
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-11-11
Pay. Date : 2012-11-27
DMF Number : 4884
Submission : 1983-03-15
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5891
Submission : 1985-06-28
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 49812-0132
Start Marketing Date : 1996-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
NDC Package Code : 51634-0014
Start Marketing Date : 1987-07-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63275-4100
Start Marketing Date : 2017-01-01
End Marketing Date : 2025-09-01
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 59116-4490
Start Marketing Date : 2012-10-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59116-4751
Start Marketing Date : 2014-10-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 61960-9193
Start Marketing Date : 2011-06-21
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51552-0677
Start Marketing Date : 2004-09-01
End Marketing Date : 2025-08-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 0406-1559
Start Marketing Date : 2011-12-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51927-0331
Start Marketing Date : 2024-04-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 0792-0543
Start Marketing Date : 2006-05-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
RLD : Yes
TE Code :
HYDROCODONE BITARTRATE; IBUPROFEN
Brand Name : VICOPROFEN
Dosage Form : TABLET;ORAL
Dosage Strength : 7.5MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 1997-09-23
Application Number : 20716
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Brand Name : VICODIN HP
Dosage Form : TABLET;ORAL
Dosage Strength : 660MG;10MG
Approval Date : 1996-09-23
Application Number : 40117
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Brand Name : VICODIN
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG;5MG
Approval Date : 1983-01-07
Application Number : 88058
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Brand Name : VICODIN ES
Dosage Form : TABLET;ORAL
Dosage Strength : 750MG;7.5MG
Approval Date : 1988-12-09
Application Number : 89736
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
RLD : No
TE Code :
ASPIRIN; HYDROCODONE BITARTRATE
Brand Name : HYDROCODONE BITARTRATE AND ASPIRIN
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG;5MG
Approval Date : 2021-05-28
Application Number : 205479
RX/OTC/DISCN : RX
RLD : No
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Brand Name : HYDROCODONE BITARTRATE AND ACETAMINOPHEN
Dosage Form : SOLUTION;ORAL
Dosage Strength : 500MG/15ML;7.5MG/15ML
Approval Date : 1992-08-28
Application Number : 81051
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Brand Name : HYDROCODONE BITARTRATE AND ACETAMINOPHEN
Dosage Form : CAPSULE;ORAL
Dosage Strength : 500MG;5MG
Approval Date : 1989-11-30
Application Number : 81067
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Brand Name : HYDROCODONE BITARTRATE AND ACETAMINOPHEN
Dosage Form : CAPSULE;ORAL
Dosage Strength : 500MG;5MG
Approval Date : 1989-11-30
Application Number : 81068
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Brand Name : HYDROCODONE BITARTRATE AND ACETAMINOPHEN
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG;5MG
Approval Date : 1986-07-16
Application Number : 89271
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Brand Name : HYDROCODONE BITARTRATE AND ACETAMINOPHEN
Dosage Form : SOLUTION;ORAL
Dosage Strength : 500MG/15ML;5MG/15ML
Approval Date : 1992-04-29
Application Number : 89557
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Dosage Form : Tablet, Orodispersible Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Application : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Excipient Details : Compressol® SM, co-processed polyol, is a DC excipient of mannitol & sorbitol with superior compactibility, low disintegration time & hygroscopicity.
Dosage Form : Capsule, Granule / Pellet, Suspension, Syrup, Tablet
Grade : Oral
Category : Coating Systems & Additives, Fillers, Diluents & Binders, Taste Masking, Thickeners and Stabilizers
Dosage Form : Capsule, Granule / Pellet, Tablet, Injectable / Parenteral
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Thickeners and Stabilizers
Application : Fillers, Diluents & Binders
Excipient Details : KoVidone® K25 is used as a low viscosity wet binder in solid dosage forms such as capsules and tablets.
Pharmacopoeia Ref : USP/NF, EP, JP, KP, IP, BP
Technical Specs : NA
Ingredient(s) : Polyvinylpyrrolidone
Dosage Form : Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Softgel Capsule, Softgels
Grade : Parenteral, Topical, Oral
Category : Fillers, Diluents & Binders, Film Formers & Plasticizers, Parenteral, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Brand Name : Polyethylene Glycol 400
Application : Fillers, Diluents & Binders, Film Formers & Plasticizers, Parenteral, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Excipient Details : PEG 400 is used as a suspending agent, stabilizer, plasticizer and filler in OSDs, liquids & semi-solids and as a solvent for parenteral formulations.
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph :
Storage :
Code/Batch No : 1587
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph :
Storage :
Code/Batch No : 1224
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph :
Storage :
Code/Batch No : 1226
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph :
Storage :
Code/Batch No : 1584
CAS Number : 125-29-1
Quantity Per Vial : 125
Sale Unit : mg
Price : $325.00
Details : USMCA- No; KORUS- Yes; Base Control Drug- HYD...
Monograph :
Storage :
Code/Batch No : Catalog #1314960 / R023C0
Hydrocodone Related Compound A CII (70 mg) (4...
CAS Number : 847-86-9
Quantity Per Vial : 70
Sale Unit : mg
Price : $924.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1315012 / R031R0
Hydrocodone Bitartrate CII (100 mg)
CAS Number : 34195-34-1
Quantity Per Vial : 100
Sale Unit : mg
Price : $576.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1315001 / N2I034
ABOUT THIS PAGE
50
PharmaCompass offers a list of Hydrocodone Bitartrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Hydrocodone Bitartrate manufacturer or Hydrocodone Bitartrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hydrocodone Bitartrate manufacturer or Hydrocodone Bitartrate supplier.
PharmaCompass also assists you with knowing the Hydrocodone Bitartrate API Price utilized in the formulation of products. Hydrocodone Bitartrate API Price is not always fixed or binding as the Hydrocodone Bitartrate Price is obtained through a variety of data sources. The Hydrocodone Bitartrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A ANEXSIA 5/325-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ANEXSIA 5/325-1, including repackagers and relabelers. The FDA regulates ANEXSIA 5/325-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ANEXSIA 5/325-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of ANEXSIA 5/325-1 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A ANEXSIA 5/325-1 supplier is an individual or a company that provides ANEXSIA 5/325-1 active pharmaceutical ingredient (API) or ANEXSIA 5/325-1 finished formulations upon request. The ANEXSIA 5/325-1 suppliers may include ANEXSIA 5/325-1 API manufacturers, exporters, distributors and traders.
click here to find a list of ANEXSIA 5/325-1 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A ANEXSIA 5/325-1 DMF (Drug Master File) is a document detailing the whole manufacturing process of ANEXSIA 5/325-1 active pharmaceutical ingredient (API) in detail. Different forms of ANEXSIA 5/325-1 DMFs exist exist since differing nations have different regulations, such as ANEXSIA 5/325-1 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A ANEXSIA 5/325-1 DMF submitted to regulatory agencies in the US is known as a USDMF. ANEXSIA 5/325-1 USDMF includes data on ANEXSIA 5/325-1's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ANEXSIA 5/325-1 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of ANEXSIA 5/325-1 suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a ANEXSIA 5/325-1 Drug Master File in Korea (ANEXSIA 5/325-1 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of ANEXSIA 5/325-1. The MFDS reviews the ANEXSIA 5/325-1 KDMF as part of the drug registration process and uses the information provided in the ANEXSIA 5/325-1 KDMF to evaluate the safety and efficacy of the drug.
After submitting a ANEXSIA 5/325-1 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their ANEXSIA 5/325-1 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of ANEXSIA 5/325-1 suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ANEXSIA 5/325-1 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for ANEXSIA 5/325-1 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture ANEXSIA 5/325-1 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain ANEXSIA 5/325-1 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ANEXSIA 5/325-1 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of ANEXSIA 5/325-1 suppliers with NDC on PharmaCompass.
ANEXSIA 5/325-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ANEXSIA 5/325-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ANEXSIA 5/325-1 GMP manufacturer or ANEXSIA 5/325-1 GMP API supplier for your needs.
A ANEXSIA 5/325-1 CoA (Certificate of Analysis) is a formal document that attests to ANEXSIA 5/325-1's compliance with ANEXSIA 5/325-1 specifications and serves as a tool for batch-level quality control.
ANEXSIA 5/325-1 CoA mostly includes findings from lab analyses of a specific batch. For each ANEXSIA 5/325-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ANEXSIA 5/325-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (ANEXSIA 5/325-1 EP), ANEXSIA 5/325-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ANEXSIA 5/325-1 USP).